Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01746732 · ClinicalTrials.gov registry record · Phase 1
A Study of Evacetrapib in Healthy Female Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01746732 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 23 participants.
The verdict
NCT01746732, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of evacetrapib on oral contraceptives (Ortho-Cyclen®) when given to healthy female participants. The amount of female hormones found in the blood will be measured and compared when taken alone and when taken with evaceptrapib. Each woman will participate in two study periods. Information about any side effects that may occur will also be collected.
Interventions
- DRUG Evacetrapib
- DRUG Ortho-Cyclen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01746732
The ClinicalTrials.gov registry entry for NCT01746732 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Evacetrapib is the first listed.
NCT01746732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01746732 about?
NCT01746732 is a clinical study titled "A Study of Evacetrapib in Healthy Female Participants". The purpose of this study is to evaluate the effects of evacetrapib on oral contraceptives (Ortho-Cyclen®) when given to healthy female participants. The amount of female hormones found in the blood will be measured and compared when taken alone and when taken with evaceptrapib. Each woman will part...
What is the current status of trial NCT01746732?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2012-12. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01746732?
The interventions under investigation include: Evacetrapib (DRUG), Ortho-Cyclen (DRUG).
Who is sponsoring clinical trial NCT01746732?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.